These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10945321)

  • 1. Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient.
    Masuda S; Uemoto S; Hashida T; Inomata Y; Tanaka K; Inui K
    Clin Pharmacol Ther; 2000 Jul; 68(1):98-103. PubMed ID: 10945321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapeutic drug monitoring of immunosuppresants].
    Hashida T; Inui K
    Rinsho Byori; 2001 Jul; 49(7):662-4. PubMed ID: 11519126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Saito H; Uemoto S; Kiuchi T; Tanaka K; Inui K
    Pharmacogenetics; 2002 Aug; 12(6):451-7. PubMed ID: 12172213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients.
    Masuda S; Uemoto S; Goto M; Fujimoto Y; Tanaka K; Inui K
    Clin Pharmacol Ther; 2004 Apr; 75(4):352-61. PubMed ID: 15060513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial dosage adjustment for oral administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant recipients.
    Masuda S; Goto M; Okuda M; Ogura Y; Oike F; Kiuchi T; Tanaka K; Inui K
    Transplant Proc; 2005 May; 37(4):1728-9. PubMed ID: 15919446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced expression of enterocyte P-glycoprotein depresses cyclosporine bioavailability in a recipient of living donor liver transplantation.
    Masuda S; Goto M; Kiuchi T; Uemoto S; Kodawara T; Saito H; Tanaka K; Inui K
    Liver Transpl; 2003 Oct; 9(10):1108-13. PubMed ID: 14526408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDR1 haplotypes conferring an increased expression of intestinal CYP3A4 rather than MDR1 in female living-donor liver transplant patients.
    Hosohata K; Masuda S; Yonezawa A; Katsura T; Oike F; Ogura Y; Takada Y; Egawa H; Uemoto S; Inui K
    Pharm Res; 2009 Jul; 26(7):1590-5. PubMed ID: 19267185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
    Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
    Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living-donor liver transplantation.
    Hashida T; Masuda S; Uemoto S; Saito H; Tanaka K; Inui K
    Clin Pharmacol Ther; 2001 May; 69(5):308-16. PubMed ID: 11371998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients.
    Masuda S; Goto M; Fukatsu S; Uesugi M; Ogura Y; Oike F; Kiuchi T; Takada Y; Tanaka K; Inui K
    Clin Pharmacol Ther; 2006 Jan; 79(1):90-102. PubMed ID: 16413244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients.
    Fukudo M; Yano I; Masuda S; Goto M; Uesugi M; Katsura T; Ogura Y; Oike F; Takada Y; Egawa H; Uemoto S; Inui K
    Clin Pharmacol Ther; 2006 Oct; 80(4):331-45. PubMed ID: 17015051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
    Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
    Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
    Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
    Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression of intestinal CYP3A4 in the piglet model.
    Nishi K; Ishii T; Wada M; Amae S; Sano N; Nio M; Hayashi Y
    Transplant Proc; 2004 Mar; 36(2):361-3. PubMed ID: 15050159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ursodeoxycholic acid on P-glycoprotein and cytochrome P450 3A4-dependent pharmacokinetics in humans.
    Becquemont L; Glaeser H; Drescher S; Hitzl M; Simon N; Murdter TE; Heinkele G; Hofmann U; Schaefer C; Burk O; Verstuyft C; Eichelbaum M; Fromm MF
    Clin Pharmacol Ther; 2006 May; 79(5):449-60. PubMed ID: 16678547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.
    von Ahsen N; Richter M; Grupp C; Ringe B; Oellerich M; Armstrong VW
    Clin Chem; 2001 Jun; 47(6):1048-52. PubMed ID: 11375290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole.
    Zhao W; Fakhoury M; Maisin A; Baudouin V; Storme T; Deschênes G; Jacqz-Aigrain E
    Ther Drug Monit; 2012 Dec; 34(6):739-41. PubMed ID: 23042259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.